ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.63 USD 1.87%
Market Cap: 72.4m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Operating Income
-$34.4m
CAGR 3-Years
3%
CAGR 5-Years
-23%
CAGR 10-Years
-28%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Operating Income
-CA$7.4m
CAGR 3-Years
-148%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Operating Income
$9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Income
-$24.9m
CAGR 3-Years
46%
CAGR 5-Years
19%
CAGR 10-Years
-6%
Covalon Technologies Ltd
XTSX:COV
Operating Income
-CA$1.4m
CAGR 3-Years
48%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Operating Income
-CA$14.1m
CAGR 3-Years
-20%
CAGR 5-Years
-38%
CAGR 10-Years
-2%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
72.4m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.86 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Operating Income?
Operating Income
-34.4m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Operating Income amounts to -34.4m USD.

What is ESSA Pharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-28%

Over the last year, the Operating Income growth was -7%. The average annual Operating Income growth rates for ESSA Pharma Inc have been 3% over the past three years , -23% over the past five years , and -28% over the past ten years .

Back to Top